Literature DB >> 22285935

Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats.

D A Velázquez-Zamora1, L M Garcia-Segura, I González-Burgos.   

Abstract

Estradiol and some selective estrogen receptor modulators (SERMs) are neuroprotective in a variety of experimental models of neurodegeneration, reduce the inflammatory response of glial cells, reduce anxiety and depression, promote cognition and modulate synaptic plasticity in the hippocampus of rodents. In this study we have assessed whether estradiol and two SERMs currently used in clinics, tamoxifen and raloxifene, affect medial prefrontal cortex function and morphology. Rats were ovariectomized and six days later some animals received a subcutaneous injection of the estrogenic compounds. In a first experiment animals were treated with estradiol benzoate or sesame oil vehicle. In a second experiment animals received raloxifene, tamoxifen or dimethyl sulfoxide as vehicle. Twenty four hours after the pharmacological treatment, animals were challenged to solve an allocentric working memory paradigm in a "Y" maze. Twenty trials consisting of a study phase and a test phase were conducted according to a delayed match-to-sample procedure in a single one-day session. Animals that were not submitted to behavioral test were used for Golgi analysis of the prefrontal cortex. Rats treated with estradiol benzoate, tamoxifen or raloxifene performed better in the Y maze and showed a significant increase in the numerical density of dendritic spines in secondary apical dendrites of layer III pyramidal neurons from the prelimbic/infralimbic prefrontal cortex, compared to their respective control groups. These findings suggest that estradiol, tamoxifen and raloxifene improve prefrontal cortex-related cognitive performance and modulate prefrontal cortex morphology in ovariectomized rats.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285935     DOI: 10.1016/j.yhbeh.2012.01.010

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  33 in total

Review 1.  The evolving role of dendritic spines and memory: Interaction(s) with estradiol.

Authors:  Maya Frankfurt; Victoria Luine
Journal:  Horm Behav       Date:  2015-05-17       Impact factor: 3.587

Review 2.  Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?

Authors:  Wilbert Zwart; Huub Terra; Sabine C Linn; Sanne B Schagen
Journal:  Nat Rev Clin Oncol       Date:  2015-07-21       Impact factor: 66.675

Review 3.  Neuropsychiatric effects of tamoxifen: Challenges and opportunities.

Authors:  Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck
Journal:  Front Neuroendocrinol       Date:  2020-08-18       Impact factor: 8.606

Review 4.  Actions and interactions of estradiol and glucocorticoids in cognition and the brain: Implications for aging women.

Authors:  Alexandra Ycaza Herrera; Mara Mather
Journal:  Neurosci Biobehav Rev       Date:  2015-04-27       Impact factor: 8.989

5.  Selective estrogen receptor modulators (SERMs) enhance neurogenesis and spine density following focal cerebral ischemia.

Authors:  Mohammad M Khan; Chandramohan Wakade; Liesl de Sevilla; Darrell W Brann
Journal:  J Steroid Biochem Mol Biol       Date:  2014-05-09       Impact factor: 4.292

Review 6.  Sex differences in anxiety and emotional behavior.

Authors:  Nina C Donner; Christopher A Lowry
Journal:  Pflugers Arch       Date:  2013-04-16       Impact factor: 3.657

Review 7.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 8.  Interactions between estradiol, BDNF and dendritic spines in promoting memory.

Authors:  V Luine; M Frankfurt
Journal:  Neuroscience       Date:  2012-10-16       Impact factor: 3.590

9.  Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.

Authors:  Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; José Franco; Eva Miquel; Julio César Reyes; Mercedes Roca
Journal:  Schizophr Bull       Date:  2015-11-20       Impact factor: 9.306

10.  Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women.

Authors:  Paul Newhouse; Kimberly Albert; Robert Astur; Julia Johnson; Magdalena Naylor; Julie Dumas
Journal:  Neuropsychopharmacology       Date:  2013-07-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.